Table 2.
Differentially expressed peptides
| Precursor | Peptide | Sequence | F-test FDR adj. p-value1 |
Age effect log2 fold change |
Sex effect log2 fold change | EE2 effect log2 fold change |
Interactions2 |
|---|---|---|---|---|---|---|---|
| ACBP | ODN-peptide | TVGDVNTDRPGMLDF | p < 0.001 | 3.80*** | p < 0.01 | ||
| CBLN1 | Cerebellin-1 | SGSAKVAFSAIRSTNH | n.s. | n.s. | |||
| CBLN4 | Cerebellin-4 | ANSKVAFSAVRSTN | n.s. | n.s. | |||
| CBLN4 | Cerebellin-4 | SKVAFSAVRSTN | n.s. | n.s. | |||
| GRP | GRP | APLQPGGSPALTKIYPR | p < 0.001 | 1.08*** | -0.59*** | n.s. | |
| GnIH | GnIH-RP2 | ARSSIQSLLNLSQ | p < 0.001 | 3.41*** | -0.94* | p < 0.01 | |
| PNOC | PNOC | AVASPLQVSELL | p < 0.001 | 1.62*** | n.s. | ||
| PNOC | Nociceptin | YGGFIGVRKSARKWNNQ | p < 0.001 | 1.56*** | p < 0.05 | ||
| PNOC | Nociceptin | YGGFIGVRKSA | p < 0.01 | 0.75*** | 0.45* | p < 0.05 | |
| PNOC | Neuropeptide1 | GSWPAARGVQ | p < 0.001 | 1.24*** | 0.29* | n.s. | |
| PNOC | Neuropeptide2 | FSEFLKQYLGMSPR | p < 0.001 | 1.17*** | n.s. | ||
| PNOC | Neuropeptide2 | SEFLKQYLGMSPR | p < 0.001 | 2.24*** | n.s. | ||
| PENK | Precursor | ELYHPESEDEANGGEILA | n.s. | n.s. | |||
| PENK | Precursor | SPELEDEAKELQ | p < 0.001 | 0.92*** | n.s. | ||
| PENK | Precursor | SPELEDEAKEL | p < 0.001 | 2.36*** | 0.57* | n.s. | |
| PENK | Precursor | LEDEAKELQ | p < 0.001 | 1.76*** | n.s. | ||
| PENK | Precursor | VGRPEWWLDYQ | p < 0.001 | 0.96*** | 0.51* | p < 0.05 | |
| PENK | MERF | YGGFMRF | p < 0.001 | 1.59*** | n.s. | ||
| PENK | MERSL | YGGFMRSL | p < 0.001 | 0.95*** | 0.35* | n.s. | |
| PENKB | Precursor | PKLKWDNQ | p < 0.01 | 2.36*** | n.s. | ||
| PPT | CTFP | SLNSGSSERSIAQNYE | n.s. | 0.66** | n.s. | ||
| PPT | CTFP (1P) | SLNSGSSERSIAQNYE | p < 0.001 | 1.28*** | n.s. | ||
| PPT | CTFP (2P) | SLNSGSSERSIAQNYE | p < 0.05 | 0.92*** | n.s. | ||
| PPT | SP | RPRPQQFFGLM | p < 0.001 | 1.80*** | n.s. | ||
| PPT | NPK | DAGYGQISH | n.s. | -0.99*** | p < 0.05 | ||
| PPT | NKA | HKTDSFVGLM | p < 0.001 | 1.78*** | n.s. | ||
| SCG1 | SCG1 | IHEGEEGEAEEE | n.s. | n.s. | |||
| SCG2 | Secretoneurin | TNEIVEEQYTPQSL | n.s. | 0.40* | n.s. | ||
| SCG2 | SCG2 | SGKLSFLEDE | p < 0.001 | 2.40*** | p < 0.05 | ||
| SCG5 | CTP | SVNPYLQGKRLDNVVA | p < 0.001 | 1.12*** | 0.18* | n.s. | |
| SCG5 | CTP | SVNPYLQGKRLDNVV | p < 0.001 | 2.64*** | n.s. | ||
| SMS | SMS-14 | KNFFWKTFTSC | p < 0.001 | 2.62*** | p < 0.05 | ||
| SMS | SMS-14 | FWKTFTSC | p < 0.001 | 2.70*** | n.s. | ||
| SMS | SMS-28 | SANSNPALAPRE | p < 0.001 | 1.03*** | n.s. | ||
| VIP | VIP | AVFTDNYSRF | p < 0.001 | 2.76*** | n.s. | ||
| CRMP-2 | APPGGRANITSLG | p < 0.01 | -0.82** | p < 0.01 | |||
| PPIA/FKBP12 | ANAGPNTNGSQFFICTA | p < 0.001 | -0.55*** | -0.29* | n.s. | ||
| Thymosin beta | SDKPDMAEIEKFDK | n.s. | n.s. |
1. The F-test describes the significance of the linear model that incorporates the three parameters in this study: age (ed12 and ed17, sex (male and female), and exposure (controls and EE2 exposed). There are three levels of statistical significance for the parameter effects: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). A minus sign (-) in the age effect column means that the peptide is more highly expressed in ed12 than ed17. A minus sign (-) in the sex effect column means that the peptide is more highly expressed in males compared to females. A minus sign (-) in the EE2 effect column means that the peptide is more highly expressed in controls compared to exposed. 2. The significance of the interaction effects was calculated by Walds F-test. n.s. means non-significant.